Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Résumé fourni par la source

De-identified patient-level clinical and molecular data from NCT00046930 will be deposited into the National Institutes of Health’s NCTN/NCORP Data Archive ( https://nctn-data-archive.nci.nih.gov ) 6 months after publication. De-identified patient-level next generation sequencing data files will be deposited into the National Cancer Institute’s Cancer Data Service Portal ( https://datacommons.cancer.gov/repository/cancer-data-service ) 6 months after publication. Clinical and molecular data from validation cohort II are available upon request from carroll2@mail.med.upenn.edu. This manuscript utilized data from Dataset NCT00049517-D2 from the NCTN/NCORP Data Archive of the National Cancer Institute’s (NCI’s) National Clinical Trials Network (NCTN). Data were originally collected from clinical trial NCT00049517 entitled “Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia”. All analyses and conclusions in this manuscript are the sole responsibility of the authors and do not necessarily reflect the opinions or views of the clinical trial investigators, the NCTN, the NCORP or the NCI. During the review process, requested data files were available upon request to editorial staff and reviewers through direct invitations from the corresponding author (fg5q@virginia.edu) to a confidential Box folder.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.